For instance, a patient with detected KRAS and GNAS mutations may undergo early resection of an IPMN, averting potential malignancy and aligning with personalized treatment strategies [89,90]. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.